Clinical application of18F-FUdR in glioma patients ? PET study of nucleic acid metabolism

Kameyama, Motonobu; Ishiwata, Kiichi; Tsurumi, Y.; Itoh, Jun; Sato, Kiyotaka; Katakura, Ryuichi; Yoshimoto, Takashi; Hatazawa, Jun; Ito, Masako; Ido, Tatsuo

doi:10.1007/bf01058459

Cited by 15 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their radiolabeled metabolites, which are not incorporated into DNA, may dominate the signal originating from tracer incorporated into DNA, particularly since these metabolites cross the BBB and therefore contribute to``BBB images'' (see above:``Quantitation of tumor tracer uptake''). In a number of PET studies employing short-lived radioisotopes (C-11 and F-18, with a half-life of 20 and 110 min, respectively) it has not been validated whether the PET signal obtained from tumor in fact re¯ected the DNA synthesis rates (Vander Borght et al 1994;Kameyama et al 1995;Shields et al 1998;Eary et al 1999).…”

Section: Proliferationmentioning

confidence: 99%

PET in neuro-oncology

Roelcke

Leenders²

2001

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

This article reviews possible clinical applications of positron emission tomography (PET) in brain tumor patients. PET allows quantitative assessment of brain tumor pathophysiology and biochemistry. It therefore provides different information about tumors when compared to histological or neuroradiological methods. Common clinical indications for PET comprise tumor delineation and identification of the metabolically most active tumor regions (target for biopsy, differentiation of viable tumor from necrosis). Further, the spatial relation between brain activated e.g., by speech, and the tumor bulk can be explored by activation studies. PET could also aid in the prediction of treatment response by measurement of tumor perfusion or hypoxia. Moreover, PET tracers could identify treatment targets e.g., gene products. The latter topic has not been systematically evaluated in human patients.

show abstract

Section: Proliferationmentioning

confidence: 99%

PET in neuro-oncology

Roelcke

Leenders²

2001

Journal of Cancer Research and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Because the fluorinated pyrimidines are converted to nucleotide forms by several enzymes in nucleic acid metabolism, we have proposed 18 Flabeled 2'-deoxy-5-fluorouridine (18 F-FdUrd) as a radiopharmaceutical for the nucleic acid metabolism to assess cancer viability in vivo by positron emission tomography (PET). [2][3][4][5][6][7][8][9][10][11][12][13] High grade gliomas were clearly visualized and the accumulation of 18F-FdUrd was higher than that in the low grade glioma or surReceived November 25, 1992, revision accepted March 19, 1993. For reprints contact: Kiichi Ishiwata, Ph. D., Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1 Naka-cho, Itabashi-ku, Tokyo 173, JAPAN.…”

Section: Introductionmentioning

confidence: 99%

Brain tumor accumulation and plasma pharmacokinetic parameters of 2′-deoxy-5-18F-fluorouridine

et al. 1993

Self Cite

View full text Add to dashboard Cite

Using positron emission tomography and radio-high performance liquid chromatography, the accumulation of 2'-deoxy-5-18F-fluorouridine in the brain tumors and plasma pharmacokinetic parameters were investigated in 20 patients. High accumulation of the tracer in high grade gliomas and meningiomas and very rapid degradation of the tracer in the plasma were found. Very large variations were observed in both tumor accumulation and pharmacokinetic data. The tumor accumulation, however, did not correlate with any of the plasma pharmacokinetic parameters: area under the plasma concentration-time curve, mean residence time, total body clearance and steady-state volume of distribution. The results suggest that the accumulation of the tracer reflects the metabolic activity of the brain tumor tissues and that the effect of the rapid metabolic change in the tracer in the plasma on the tumor accumulation may be minor.

show abstract

Labeled Pyrimidines in PET Imaging

Shields

Positron Emission Tomography

View full text Add to dashboard Cite

Clinical application of18F-FUdR in glioma patients ? PET study of nucleic acid metabolism

Cited by 15 publications

References 36 publications

PET in neuro-oncology

PET in neuro-oncology

Brain tumor accumulation and plasma pharmacokinetic parameters of 2′-deoxy-5-18F-fluorouridine

Labeled Pyrimidines in PET Imaging

Contact Info

Product

Resources

About